Boehringer Ingelheim has opened a €60m ($ ... Especially in the field of oncology, there is still a massive unmet medical need. We are working with great enthusiasm to make cancer a treatable ...

Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...

Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

Boehringer Ingelheim, a biopharmaceutical company active in ... the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. The WHO ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug ...

The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by ...

Boehringer Ingelheim and the WHO Foundation have partnered to promote equitable healthcare access and suicide prevention, with a focus on vulnera ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...